Biologics comparability protocol approval could lessen manufacturing changes reporting -- CBER's Zoon.
Executive Summary
BIOLOGICS "COMPARABILITY PROTOCOL" COULD LESSEN REPORTING REQUIREMENTS, under the final rule on changes to an approved application, Center for Biologics Evaluation & Research Director Kathryn Zoon told a Food & Drug Law Institute conference on July 23. The comparability protocol "will allow the manufacturer to reduce the level of risk by putting it in a lower category based on protocol defining how you are going to do the comparison study." Zoon said that "essentially a substantial risk item moves to a moderate risk, and likewise a moderate risk might move down to an annual report-type notification, depending on its comparability protocol."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: